At the presentation of operational highlights and financial results for the third quarter ended 30 September 2022, Intellia Therapeutics, Inc. President and CEO John Leonard, M.D., says:
“During the most recent quarter, Intellia has achieved significant clinical milestones. Interim data from our in vivo program, NTLA-2002, demonstrated robust reductions in both plasma kallikrein levels and the rate of swelling attacks in patients with HAE. These initial data support the potential for a single dose of NTLA-2002 to permanently prevent the debilitating and potentially fatal HAE attacks that characterize this lifelong genetic disease. We look forward to presenting additional data from NTLA-2002 later this month.The interim datasets demonstrate the modularity of our CRISPR-based platform, providing powerful evidence of our ability to apply this technology broadly to address a wide range of diseases.”
(Source: Intellia)
